Kết quả xạ trị điều biến liều kết hợp đồng thời cisplatin bệnh ung thư hạ họng giai đoạn III-IVb tại Bệnh viện Ung bướu Nghệ An

Abstract

Objective: To describe some clinical and paraclinical characteristics and evaluate the results of a group of patients with stage III-IVB hypopharyngeal cancer who were treated by intensity-modulated radiation therapy concomitant with cisplatin regimen at Nghe An Oncology Hospital. Subject and method: A descriptive study on 45 patients with stage III-IVb hypopharyngeal cancer at Nghe An Oncology Hospital from January 2020 to march 2022. The patients received intensity-modulated radiation therapy concomitant with cisplatin every 3 weeks. Result: Mean age 58.2 ± 8.1, 100% of patients were male. The ratio of patients with swallowing disorder was 73.3% and self-palpable cervical lymph nodes was 20.0%. Tumor was located at the piriform sinus (75.56%), There were 15 (33.3%) patients at stage III and 30 (66.7%) patients at stage IVA-B. The rate of complete response after chemoradiotherapy was 48.9%, the partial response rate was 46.7%. Overall survival at 12 months and 24 months were 88.8% and 40.6%, respectively; disease-free survival at 12 months was 57.7%. Severe toxicity on hematopoietic system (Grade 3-4): neutropenia 13.3% (6 patients), thrombocytopenia 4.4% (2 patients), no patient suffered side effects grade 3-4 on liver and kidney. Dermatitis, mucositis grade ≥ 2 were 24.4% and 37.8%, respectively. Conclusion: The regimen has a good response rate, safety, and acceptable toxicity.